A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer - Trial NCT05908734
Access comprehensive clinical trial information for NCT05908734 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Janssen Research & Development, LLC and is currently Recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Janssen Research & Development, LLC
Timeline & Enrollment
Phase 1/2
May 18, 2023
Sep 28, 2025
Primary Outcome
Phase 1: Number of Participants with Adverse events (AEs) by Severity,Phase 1: Number of Participants with Dose Limiting Toxicities (DLTs),Phase 2: Objective Response Rate
Summary
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD)
 of the amivantamab and cetrelimab combination therapy in participants with non-small cell
 lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor
 effect of the combination at the selected RP2CD in participants with NSCLC characterized by
 epidermal growth factor receptor (EGFR) exon19del or exon 21 leucine 858 to arginine
 substitution (L858R) mutations, who have progressed on or after prior standard of care
 therapy with a 3rd generation tyrosine kinase inhibitor (TKI) and platinum-based
 chemotherapy, in the Phase 2 (expansion).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05908734
Non-Device Trial